Cluster of differentiation 81 (CD81) (CD81)

Cluster of differentiation 81 (CD81), also known as TAPA-1, is a member of the tetraspanin family of proteins characterized by four transmembrane domains. It plays a pivotal role in organizing tetraspanin-enriched microdomains (TEMs) on the cell surface, which facilitate various cellular processes including adhesion, motility, and signal transduction [1, 5]. CD81 is most notably recognized as an essential co-receptor for the Hepatitis C virus (HCV), where it interacts with the viral E2 glycoprotein to mediate viral entry into hepatocytes [2, 4]. Additionally, CD81 is a key component of the B-cell receptor complex, influencing B-cell activation and the immune response [3]. It is also widely used as a marker for extracellular vesicles, particularly exosomes, reflecting its role in vesicle biogenesis [5]. In the context of oncology, CD81 has been implicated in tumor cell migration and metastasis in several malignancies, including melanoma and breast cancer. Therapeutic strategies targeting CD81 primarily focus on monoclonal antibodies to prevent viral infection or inhibit tumor progression, though its broad tissue distribution necessitates careful evaluation of potential systemic toxicities.

Other names

TAPA1TSPAN28Tetraspanin-28Target of antiproliferative antibody 1S5.7CD81 molecule

The primary mechanism of action for drugs targeting CD81 involves the use of monoclonal antibodies to sterically hinder the interaction between the CD81 large extracellular loop (LEL) and viral glycoproteins, such as the HCV E2 protein, thereby preventing viral entry [2, 4]. Additionally, experimental approaches using small interfering RNA (siRNA) target the CD81 mRNA transcript to induce its degradation, leading to reduced protein expression and subsequent inhibition of CD81-dependent processes like viral replication [4]. In oncology, targeting CD81 aims to disrupt tetraspanin-enriched microdomains, which can inhibit tumor cell signaling, migration, and metastatic potential [5].